OSTX · OS Therapies Incorporated

Summary

OS Therapies Incorporated entered into a securities purchase agreement on March 4, 2026, issuing $2,200,000 aggregate principal amount of 10.0% OID unsecured convertible promissory notes and warrants to purchase up to 1,666,667 shares of common stock for $2,000,000 gross proceeds in a private placement. The net proceeds will fund clinical development activities, ongoing and planned clinical trials, research and development programs, working capital, and general corporate purposes.

Key takeaways

• Private Placement closed March 4, 2026 with accredited investors
• Notes: $2,200,000 principal at 10% OID, 4% interest, mature March 4, 2027
• Warrants: up to 1,666,667 shares at $1.40 exercise price, 5-year term
• Gross proceeds: $2,000,000 before 7% placement agent fee and $25,000 expense reimbursement
• Placement agent: SEC-registered broker-dealer and FINRA member
• Conversion: voluntary at 90% of 10-day VWAP; mandatory in Qualified Offering at offering price